Experimental ovarian cancer therapy targets stubborn tumors
NCT ID NCT06342986
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This early-stage trial tests a new treatment called FT536 for people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after prior therapy. The treatment is given directly into the abdomen three times in one week, after a short course of chemotherapy to prepare the body. The main goal is to see if the treatment can slow or stop cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.